June 2020 // Communication

Updated: Mar 19, 2021

Synendos Therapeutics received a prestigious European grant (SME Instrument Phase I, TWO-BIRDS project ) that helped the company to head towards clinical trials. The European commission is now reporting about the results and the perspectives to treat post-traumatic stress disorder (PTSD) and other neuropsychiatric diseases. Read the full article here.



Recent Posts

See All

Synendos Therapeutics is ranked TOP 100 Swiss Startups 2022 We are honored to be listed for the second year in a row as one of the TOP 100 Swiss Startups 2022. A big thank you to our team, partners, c

In a last newsletter edition from NCCR Transcure, we can look behind the scenes of our technology transfer success story.